产品
编 号：F754348
分子式：C21H20F3N5O3
分子量：447.41
分子式：C21H20F3N5O3
分子量：447.41
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2648641-36-3
产品详情
生物活性：
Zotizalkib (TPX-0131) is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). Zotizalkib has strong antitumor activities.
体内研究：
Zotizalkib (2-10 mg/kg；口服；每天两次；持续 2 周) 2mg /kg、5mg /kg 和10mg /kg 的剂量依赖性肿瘤生长抑制(TGI)分别为64%、120% 和 200%(完全回归)。Animal Model:Female SCID/beige mice (5-8 weeks old) bearing Ba/F3 cells
Dosage:2 mg/kg, 5 mg/kg, and 10 mg/kg
Administration:p.o.; twice a day; for 2 weeks
Result:Caused complete tumor regression in ALK mutation-dependent xenograft models.
体外研究：
Zotizalkib 有效抑制野生型 ALK (IC50=1.4 nM) 和 26 种 ALK 耐药突变。 Zotizalkib 抑制 C1156Y、E1210K/S1206C、L1198F/C1156Y、L1196M/L1198F、E1210K、L1196M、T1151M、缺失的 G1202、S1206R、G1202R/L1198F、F1174L、F1245C、R12 75Q 和 G1202R ALK 突变，IC50 值 Zotizalkib 相关抗体:
Zotizalkib (TPX-0131) is a potent, selective, CNS-penetrant and orally active inhibitor of wild-type ALK (IC50 of 1.4 nM) and ALK-resistant mutation, e.g. G1202R (IC50 of 0.3 nM), L1196M (IC50 of 0.3 nM). Zotizalkib has strong antitumor activities.
体内研究：
Zotizalkib (2-10 mg/kg；口服；每天两次；持续 2 周) 2mg /kg、5mg /kg 和10mg /kg 的剂量依赖性肿瘤生长抑制(TGI)分别为64%、120% 和 200%(完全回归)。Animal Model:Female SCID/beige mice (5-8 weeks old) bearing Ba/F3 cells
Dosage:2 mg/kg, 5 mg/kg, and 10 mg/kg
Administration:p.o.; twice a day; for 2 weeks
Result:Caused complete tumor regression in ALK mutation-dependent xenograft models.
体外研究：
Zotizalkib 有效抑制野生型 ALK (IC50=1.4 nM) 和 26 种 ALK 耐药突变。 Zotizalkib 抑制 C1156Y、E1210K/S1206C、L1198F/C1156Y、L1196M/L1198F、E1210K、L1196M、T1151M、缺失的 G1202、S1206R、G1202R/L1198F、F1174L、F1245C、R12 75Q 和 G1202R ALK 突变，IC50 值 Zotizalkib 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备